# **PCT**

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference P2004-0322WO	FOR FURTHER ACTION	See item 4 below		
International application No. PCT/JP2004/004861	International filing date (day/month/year) 02 April 2004 (02.04.2004)	Priority date (day/month/year) 03 April 2003 (03.04.2003)		
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237				
Applicant KAO CORPORATION				

1.	<ol> <li>This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).</li> </ol>			
2.	This REPORT consists of a total	of 6 sheets, including this cov	ver sheet.	
	In the attached sheets, any reference to the international preliminary re	nce to the written opinion of t eport on patentability (Chapte	he International Searching Authority should be read as a reference r I) instead.	
3.	This report contains indications r	elating to the following items	:	
	Box No. I	Basis of the report		
	Вох №. П	Priority		
	Box No. III	Non-establishment of opin applicability	ion with regard to novelty, inventive step and industrial	
	Box No. IV	Lack of unity of invention		
	Box No. V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
	Box No. VI Certain documents cited			
	Box No. VII	Certain defects in the inter	national application	
	Box No. VIII Certain observations on the international application			
4.	4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).			
	Date of issuance of this report 02 March 2006 (02.03.2006)			
	The International Burea 34, chemin des Colo 1211 Geneva 20, Sw	ombettes	Authorized officer  Masashi Honda	
Facsi	Facsimile No. +41 22 740 14 35		Telephone No. +41 22 338 70 10	

Form PCT/IB/373 (January 2004)

From the INTERNATIONAL SEARCHING AUTHOR	ITY		* * * * * * * * * * * * * * * * * * *	
То:		We	PCT PT STATE OF THE	
			ONAL SEARCHING AUTHORITY	
			(PCT Rule 43bis.1)	
	l <sub>i</sub>	Date of mailing		
		(day/month/year)		
Applicant's or agent's file reference		FOR FURTHER A		
P2004-0322WO	Tananaka al Elia dan (	d((	See paragraph 2 below	
International application No. PCT/JP2004/004861	International filing date (d) 02.04.2004	iaymoninyear)	Priority date (day/month/year) 03.04.2003	
International Patent Classification (IPC) or both	national classification and	TIPC		
Applicant				
KAO CORPORATION				
This opinion contains indications rela	ting to the following items:	:		
Box No. I Basis of the	opinion			
Box No. II Priority				
Box No. III Non-establi	shment of opinion with reg	ard to novelty, inventi	ive step and industrial applicability	
Box No. IV Lack of unit	ty of invention			
	atement under Rule 43bis. y; citations and explanation		novelty, inventive step or industrial ement	
Box No. VI Certain doc	uments cited			
Box No. VII Certain defe	ects in the international app	pplication		
Box No. VIII Certain obs	ervations on the internation	nal application		
2. FURTHER ACTION				
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of th International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.				
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Fo PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.			of 3 months from the date of mailing of Form	
For further options, see Form PCT/ISA/220.				
3. For further details, see notes to Form PCT/ISA/220.				
Name and mailing address of the ISA/ID		Authorized officer		
Name and mailing address of the ISA/JP		Addition 2ed officer		
Facsimile No.		Telephone No.		

Imernational application No.
PCT/JP2004/004861

Box	No. I Basis of this opinion	
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it will filed, unless otherwise indicated under this item.	as
	This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (und	<b>c</b> r
	Rule 12.3 and 23.1(b)).	
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claim invention, this opinion has been established on the basis of:	ed
	a. type of material	
	a sequence listing	
	table(s) related to the sequence listing	
	b. format of material	
	in written format	
	in computer readable form	
	c. time of filing/furnishing	
	contained in the international application as filed.	
	filed together with the international application in computer readable form.	
	furnished subsequently to this Authority for the purposes of search.	
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application filed or does not go beyond the application as filed, as appropriate, were furnished.	
4.	Additional comments:	
İ		
1		

International application No.
PCT/JP2004/004861

Box No. III	Non-establishment of opinion	with regard to novelty, inventive step and industrial app	licability
	ons whether the claimed invention app have not been examined in respect of:	ocars to be novel, to involve an inventive step (to be no	n obvious), or to be industrially
	the entire international application		
	claims Nos. 9-21, 23		
because	e:		
	the said international application, or the relate to the following subject matter where	said claims Nos. 9-21, 23 hich does not require an international preliminary examination	on (specify):
	fluorescent light data from th	s 9-21, 23 relate to a method for detecting can be measured area, which does not require an the International Preliminary Examining Au and Rule 39.1(iv).	international
1	the description, claims or drawings (ind are so unclear that no meaningful opinion	licate particular elements below) or said claims Nos.  on could be formed (specify):	
	the claims, or said claims Nos.		are so inadequately supported
_	by the description that no meaningful o	pinion could be formed.	
	no international search report has been	established for said claims Nos.	
	the nucleotide and/or amino acid seque Instructions in that:	ence listing does not comply with the standard provided for	in Annex C of the Administrative
	the written form	has not been furnished	
		does not comply with the standard	
	the computer readable form	has not been furnished	
		does not comply with the standard	
		Vor amino acid sequence listing, if in computer readable for Annex C-bis of the Administrative Instructions.	orm only, do not comply with the
	See Supplemental Box for further detail	ls.	

International application No.
PCT/JP2004/004861

Box N	Box No. V Reasoned statement under Rule 43bis.1(a)(l) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1. 5	Statement			
	Novelty (N)	Claims	2, 4, 8, 22	YES
		Claims	1, 3, 5-7	NO
	Inventive step (IS)	Claims	2, 4, 22	YES
			1, 3, 5-8	NO
	Industrial applicability (IA)	Claims	1-8, 22	YES
		Claims		NO

#### 2. Citations and explanations:

Document 1: JP, 56-40137, A (Robert. R. Alfano), 16 April, 1981 (16.04.81), & FR, 2463608, A1 & DE, 3031249, A1 & GB, 2058343, A & US, 4290433, A & CA, 1161120, A & NL, 8004712, A

Document 1 describes 1) a carious tooth detection device providing a) an ultraviolet ray irradiation device, b) a fluorescent light reception device to receive the fluorescent light from the tooth caused by the ultraviolet rays irradiated from that ultraviolet ray irradiation device, c) a fluorescent data analysis section to analyze the fluorescent data transmitted from the fluorescent light reception device, and d) a display device to display the data analyzed by that fluorescent data analysis section; and 2) that the previously mentioned fluorescent data analysis section of the carious tooth detection device analyses the previously mentioned fluorescent light data on the basis of the fluorescent light intensity of two wavelength bands of the visible light region; 3) that the previously mentioned fluorescent data analysis section calculates how far the caries is advanced on the basis of the fluorescent light intensity in the first wavelength band having a wavelength width of 10 nm or less selected from a wavelength band of 560-640 nm and the fluorescent light intensity in the second wavelength band having a wavelength width of 10 nm or less selected from a wavelength band of 440-470 nm; 4) the provision of a light device able to extract data related to the previously mentioned fluorescent light intensity from the previously mentioned first wavelength band and the previously mentioned second wavelength band from the visible light region on the fluorescent light reception device; and 5) that the previously mentioned light device is a light sensor with two color filters. As a light device as the one mentioned before, spectral luminance meters, color CCD and CMOS are well known, and ultraviolet ray irradiation devices with adjustable output intensity are also well known.

#### Claim 8

Document 2: JP, 2001-24223, A (Nichia Chemical Industries, Ltd.), 26 January, 2001 (26.01.01) (Family: none)

The ultraviolet ray LED as an ultraviolet ray irradiation device is well known as described in document 2, and the idea of using an ultraviolet ray LED as the ultraviolet ray irradiation device also in the carious tooth detection device described in document 1 could have easily been conceived of by a person skilled in the art.

Claims 2, 4, 22

A carious tooth detection device performing the analysis on the basis of the fluorescent light intensity, which changes corresponding to changes in the irradiation intensity of ultraviolet rays, and a carious tooth detection device performing the analysis on the basis of the fluorescent light intensity

International application No.
PCT/JP2004/004861

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
in three o	r more wavelength bands from the visible light region are not described in any of the
documen	ts cited in the ISR, and these points are also not obvious even for persons skilled in the art.
:	

## **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 4-32899A	FOR FURTHER ACTION	See item 4 below		
International application No. PCT/EP2004/003588	International filing date (day/month/year) 05 April 2004 (05.04.2004)	Priority date (day/month/year) 14 April 2003 (14.04.2003) ]		
International Patent Classification (IPC) or national classification and IPC 7 C12Q 1/68				
Applicant NOVARTIS AG				

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis. 1(a).			
2.	This REPORT consists of a total	of 8 sheets, including this cover sheet.		
		ence to the written opinion of the International Searching Authority should be read as a reference report on patentability (Chapter I) instead.		
3.	This report contains indications	relating to the following items:		
	Box No. I	Basis of the report		
	Box No. II	Priority		
	Box No. III  Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention		
	Box No. V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
	Box No. VI	Certain documents cited		
	Box No. VII	Certain defects in the international application		
	Box No. VIII	Certain observations on the international application		
4.	4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis.2).			

	Date of issuance of this report 14 October 2005 (14.10.2005)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Yolaine Cussac
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 70 80

Form PCT/IB/373 (January 2004)

REC'D 0 4 AUG 2004

WIPO	PC

INTERNATIONAL SEARCHING AUTHORITY

To: see form PCT/ISA/220		PCT  WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)	
Applicant's or agent's file reference see form PCT/ISA/220		FOR FURTHER ACTION See paragraph 2 below	
International application No. International filing date PCT/EP2004/003588 05.04.2004		lay/month/year)	Priority date (day/month/year) 14.04.2003
International Patent Classification (IPC) or C12Q1/68	both national classification	and IPC	
Applicant NOVARTIS AG			

☐ Box No. VII ☐ Box No. VIII Certain observations on the international application

**FURTHER ACTION** 

☑ Box No. I

☑ Box No. II

☑ Box No. III

☐ Box No. IV

☑ Box No. V

☐ Box No. VI

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the international Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.

applicability; citations and explanations supporting such statement

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

For further details, see notes to Form PCT/ISA/220.

This opinion contains indications relating to the following items:

Certain defects in the international application

Basis of the opinion

Lack of unity of invention

Certain documents cited

**Priority** 

Name and mailing address of the ISA:

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

**Authorized Officer** 

Sommerfeld, T

Telephone No. +49 89 2399-7197



International application No. PCT/EP2004/003588

	Box No. I	Basis of the opinion
1.	With regard	I to the <b>language</b> , this opinion has been established on the basis of the international application in ge in which it was field, unless otherwise indicated under this item.
	langua	pinion has been established on the basis of a translation from the original language into the following ge , which is the language of a translation fumished for the purposes of international search Rules 12.3 and 23.1(b)).
2.	With regard necessary	d to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application and to the claimed invention, this opinion has been established on the basis of:
	a. type of n	naterial:
	□ as	equence listing
	☐ tab	le(s) related to the sequence listing
	b. format o	f material:
	in v	written format
	□ in o	computer readable form
	c. time of f	iling/furnishing:
	□ co	ntained in the international application as filed.
	☐ file	ed together with the international application in computer readable form.
	☐ fur	nished subsequently to this Authority for the purposes of search.
3	has b copie	dition, in the case that more than one version or copy of a sequence listing and/or table relating thereto een filed or furnished, the required statements that the information in the subsequent or additional s is identical to that in the application as filed or does not go beyond the application as filed, as opriate, were furnished.
4	. Additional	comments:

International application No. PCT/EP2004/003588

	Box	k No. II	Priority
1.	<b>Ø</b>		lowing document has not been furnished:
		⊠	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).
			translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).
		Conse	quently it has not been possible to consider the validity of the priority claim. This opinion has neless been established on the assumption that the relevant date is the claimed priority date.
2.	. 🗆	hac he	pinion has been established as if no priority had been claimed due to the fact that the priority claim the found invalid (Rules 43 <i>bis.</i> 1 and 64.1). Thus for the purposes of this opinion, the international ate indicated above is considered to be the relevant date.
3	. Ad	ditional (	observations, if necessary:

International application No. PCT/EP2004/003588

	•		at a standard ladvotelol				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability							
The c	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:						
□ t	the entire international application,						
⊠' (	claims Nos. 7, 9, 11						
beca							
⊠ 1	the said international application, or the said claims Nos. 7, 9, 11 relate to the following subject matter which does not require an international preliminary examination (specify):						
	see separate sheet						
	unclear that no meaningful opin	ion c					
	could be formed.						
	no international search report has been established for the whole application or for said claims Nos.						
	the nucleotide and/or amino aci C of the Administrative Instructi	d se	quence listing does not comply with the standard provided for in Annex in that:				
	the written form		has not been furnished				
			does not comply with the standard				
	the computer readable form		has not been furnished				
			does not comply with the standard				
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, or not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.						
☐ See separate sheet for further details							

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No:

s 5-45

Claims

Inventive step (IS)

Yes: Claims

5

1-4

No: Claims

1-4, 6-45

Industrial applicability (IA)

Yes: Claims

1-6, 8, 10, 12-45

No: Claims

2. Citations and explanations

see separate sheet

In this written opinion reference is made to the following documents:

- D1: KITCHING RICHARD ET AL: 'Coordinate gene expression patterns during osteoblast maturation and retinoic acid treatment of MC3T3-E1 cells. JOURNAL OF BONE AND MINERAL METABOLISM. JAPAN 2002, vol. 20, no. 5, 2002, pages 269-280, XP002286916 ISSN: 0914-8779
- D6: SETH ARUN ET AL: 'Coordinate expression of novel genes during osteoblast differentiation' JOURNAL OF BONE AND MINERAL RESEARCH, vol. 15, no. 9, September 2000 (2000-09), pages 1683-1696, XP009033034 ISSN: 0884-0431
- D9: MCGALL G ET AL: 'LIGHT-DIRECTED SYNTHESIS OF HIGH-DENSITY OLIGONUCLEOTIDE ARRAYS USING SEMICONDUCTOR PHOTORESISTS' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 November 1996 (1996-11-01), pages 13555-13560, XP000775688 ISSN: 0027-8424 cited in the application

The present application discloses gene profiling assays of the osteoblast-like cell lines MC3T3-E1 and MC3T3-1b to be used for screening drugs which modulate osteoblast differentiation.

### Section III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 7, 9 and 11 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 33(4)(a)(i) PCT).

#### Section V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- Document D1 discloses gene profiling of MC3T3-E1 cells in several phases of 1. differentiation and in response to retinoic acid treatment (see e.g. abstract), and provides a comparative osteoblast gene expression study (page 271 right column last paragraph, tables 1-3). It thus appears that document D1 discloses a method which comprises all the features of claim 1. Claim 1 thus lacks novelty (Art. 33(2)PCT). The same applies to claims 2-4.
- Claim 5, which is directed to the screening method of claim 1, wherein in the gene 2. analysed is Hey1, appears to be both novel and inventive, as this gene had not been associated with osteoblastic differentiation (Art. 33(2)(3)PCT).
- Claims 6-20 are directed to methods of diagnostic, treatment and screening of 3. drugs which do not appear to involve an inventive step (Art. 33(3)PCT) in view of D1 in combination with D6, which discussed the relation between manipulation of genes involved in osteoblastic differentiation and osteoporosis (page 1693 right column last 3 lines).
- Claims 21-34 refer to features which are standard in the method of DNA microarrays analysis (see e.g. document D9). These claims thus lack an inventive step (Art. 33(3)PCT).
  - The same applies to claims 35-45 which are directed to the computer implementation of the above methods.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:			
☐ BLACK BORDERS			
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES			
☐ FADED TEXT OR DRAWING			
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING			
☐ SKEWED/SLANTED IMAGES			
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS			
☐ GRAY SCALE DOCUMENTS			
☐ LINES OR MARKS ON ORIGINAL DOCUMENT			
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY			

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.